Midomafetamine

Water Tower Research published a report on Cybin, Inc., highlighting its leadership in neuropsychiatric therapeutics, rapid advancement of lead candidates CYB003 and CYB004, and differentiated deuteration technology. Cybin's market valuation is favorable compared to peers, and its well-capitalized status positions it for potential success.

Water Tower Research published an Initiation of Coverage Report on Cybin, Inc., highlighting its status as a leader in novel neuropsychiatric therapeutics. Cybin's focus on innovative treatments for mental health disorders like MDD and GAD, with lead candidates CYB003 and CYB004, positions it favorably compared to peers. The report emphasizes Cybin's rapid pipeline advancement and differentiated solutions, noting its favorable valuation and well-capitalized status.

John Raymond Jefferson, II, pleaded guilty to drug trafficking charges and will serve a minimum of 36 months in state prison. Jefferson was caught with a large amount of methamphetamine and other illegal drugs. His attorney requested a continuance on sentencing to argue his eligibility for state Department of Corrections programs.

Ketamine, a class B drug in the UK, is causing concern due to its non-medical use, leading to health issues and fatalities. Despite its medical benefits, its cheap price and fast-acting effects make it appealing, especially among young people. The rise in ketamine use has led to increased treatment seekers, highlighting the need for better prevention, education, and mental health support to mitigate harm.

Sam Altman, co-founder of OpenAI, discusses his transformative psychedelic experiences on the Life in Seven Songs podcast, crediting them with improving his mental health. Altman, now chairman of Journey Colab, aims to develop safe, effective psychedelic therapies for conditions like depression and PTSD, partnering with luxury rehab centers like All Points North. Journey Colab plans to make these therapies accessible to marginalized communities.

Psychedelic drugs are nearing prescription for European patients with mental health issues, but hurdles remain. Research on psilocybin and MDMA is ongoing, with potential to treat conditions like depression and addiction. Controversy and challenges in study replication persist, but larger-scale studies and advances in brain scan technology are providing clearer insights. The first psychedelic to hit the European market may be from UK-based Compass Pathways, which is testing psilocybin for treatment-resistant depression. The psychedelic movement faces setbacks, such as US regulators rejecting MDMA for PTSD, which could delay access in Europe.

Two men, Susheel Kumar and Palukuri Deepak, were arrested with 27 grams of MDMA by the Excise State Task Force (STF) at Jambagh flower market. Supplier Praveen Singh Rav from Bengaluru was identified, along with associates V. Ramesh and Charan. Customers Hitesh, Shaik Mohammad, and Bobby were found to be making online payments for the contraband. Susheel transported MDMA to Hyderabad via private buses, selling it at double the price.

Demand for naloxone doubled as stimulant and hallucinogenic users, fearing laced narcotics, sought the drug. Health authorities urge all drug users to carry naloxone due to synthetic opioids in illicit drugs. The Take Home Naloxone program saw a surge in supply, from 110,976 units in 2022-2023 to 243,248 in 2023-2024.

Despite MDMA-assisted therapy (MDMA-AT) showing promise for PTSD, its inaccessibility due to time, cost, and operational challenges makes it impractical for widespread use. The focus now shifts to FDA-cleared, neuroscience-based technologies that offer scalable, cost-effective PTSD treatments, addressing the critical need for accessible mental health care.